Abstract
Target identification of novel therapeutic drugs is pivotal for the establishment of (1) new anticancer regiments, (2) to control side effects of the drugs, and (3) to identify appropriate combinations with established drugs.
Here, we describe several in vitro assays applicable to characterize different characteristics of tumor cells. Furthermore, we present a protocol for establishing a reporter gene system for in vivo imaging, allowing for the study of drug effects in small animal models.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ammerpohl O et al (2007) Complementary effects of HDAC inhibitor 4-PB on gap junction communication and cellular export mechanisms support restoration of chemosensitivity of PDAC cells. Br J Cancer 96(1):73–81
Orntoft TF, Petersen SE, Wolf H (1988) Dual-parameter flow cytometry of transitional cell carcinomas. Quantitation of DNA content and binding of carbohydrate ligands in cellular subpopulations. Cancer 61(5):963–970
Asklund T et al (2004) Histone deacetylase inhibitor 4-phenylbutyrate modulates glial fibrillary acidic protein and connexin 43 expression, and enhances gap-junction communication, in human glioblastoma cells. Eur J Cancer 40(7):1073–1081
Svechnikova I, Ammerpohl O, Ekstrom TJ (2007) p21waf1/Cip1 partially mediates apoptosis in hepatocellular carcinoma cells. Biochem Biophys Res Commun 354(2):466–471
Ammerpohl O et al (2004) HDACi phenylbutyrate increases bystander killing of HSV-tk transfected glioma cells. Biochem Biophys Res Commun 324(1):8–14
Appelskog IB et al (2004) Histone deacetylase inhibitor 4-phenylbutyrate suppresses GAPDH mRNA expression in glioma cells. Int J Oncol 24(6):1419–1425
Tolboom TC, Huizinga TW (2007) In vitro matrigel fibroblast invasion assay. Methods Mol Med 135:413–421
Casey RC et al (2003) Establishment of an in vitro assay to measure the invasion of ovarian carcinoma cells through mesothelial cell monolayers. Clin Exp Metastasis 20(4):343–356
Trauzold A et al (2005) CD95 and TRAF2 promote invasiveness of pancreatic cancer cells. FASEB J 19(6):620–622
Frangioni JV (2003) In vivo near-infrared fluorescence imaging. Curr Opin Chem Biol 7(5):626–634
Weissleder R et al (1999) In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat Biotechnol 17(4):375–378
Villalobos V, Naik S, Piwnica-Worms D (2007) Current state of imaging protein-protein interactions in vivo with genetically encoded reporters. Annu Rev Biomed Eng 9:321–349
Mezzanotte L et al (2014) A new multicolor bioluminescence imaging platform to investigate NF-kappaB activity and apoptosis in human breast cancer cells. PLoS One 9(1), e85550
O’Brien MA et al (2005) Homogeneous, bioluminescent protease assays: caspase-3 as a model. J Biomol Screen 10(2):137–148
Bouvet M, Spernyak J, Katz MH, Mazurchuk RV, Takimoto S, Bernacki R, Rustum YM, Moossa AR, Hoffman RM (2005) High correlation of whole-body red fluorescent protein imaging and magnetic resonance imaging on an orthotopic model of pancreatic cancer. Cancer Res 65(21):9829–9833
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media New York
About this protocol
Cite this protocol
Tiwari, S., Ammerpohl, O., Kalthoff, H. (2016). Target Gene Discovery for Novel Therapeutic Agents in Cancer Treatment. In: Grützmann, R., Pilarsky, C. (eds) Cancer Gene Profiling. Methods in Molecular Biology, vol 1381. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-3204-7_10
Download citation
DOI: https://doi.org/10.1007/978-1-4939-3204-7_10
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-3203-0
Online ISBN: 978-1-4939-3204-7
eBook Packages: Springer Protocols